Bayer's Potential Breakup Faces Challenges Despite Supreme Court Win

Dow Jones06-26

0817 GMT - A Bayer breakup looks possible, but it shouldn't be taken for granted even if the U.S. Supreme Court ruled in the company's favor in a case over its Roundup weedkiller, Jefferies analysts say in a research note. While many think the Supreme Court ruling could make a breakup more likely, the challenges the group's pharma business would face as a standalone company remain a potential hurdle, the analysts say. The German group's pharma business is expected to grow at a slower pace than peers over the next five years, and a couple of drugs that should help drive that growth will face risk from rival products, they add. Moreover, its drug pipeline is at an early stage, and its debt load leaves little room for acquisitions, according to Jefferies. Shares fall 0.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 26, 2026 04:20 ET (08:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646201337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 16:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646201337","market":"other","top_or_hot":-1,"title":"Bayer's Potential Breakup Faces Challenges Despite Supreme Court Win","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0817 GMT - A Bayer breakup looks possible, but it shouldn't be taken for granted even if the U.S. Supreme Court ruled in the company's favor in a case over its Roundup weedkiller, Jefferies analysts say in a research note. While many think the Supreme Court ruling could make a breakup more likely, the challenges the group's pharma business would face as a standalone company remain a potential hurdle, the analysts say. The German group's pharma business is expected to grow at a slower pace than peers over the next five years, and a couple of drugs that should help drive that growth will face risk from rival products, they add. Moreover, its drug pipeline is at an early stage, and its debt load leaves little room for acquisitions, according to Jefferies. Shares fall 0.6%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2026 04:20 ET (08:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer's Potential Breakup Faces Challenges Despite Supreme Court Win</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer's Potential Breakup Faces Challenges Despite Supreme Court Win\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-26 16:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0817 GMT - A Bayer breakup looks possible, but it shouldn't be taken for granted even if the U.S. Supreme Court ruled in the company's favor in a case over its Roundup weedkiller, Jefferies analysts say in a research note. While many think the Supreme Court ruling could make a breakup more likely, the challenges the group's pharma business would face as a standalone company remain a potential hurdle, the analysts say. The German group's pharma business is expected to grow at a slower pace than peers over the next five years, and a couple of drugs that should help drive that growth will face risk from rival products, they add. Moreover, its drug pipeline is at an early stage, and its debt load leaves little room for acquisitions, according to Jefferies. Shares fall 0.6%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2026 04:20 ET (08:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646201337","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646201337","pubTimestamp":1782462000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0817 GMT - A Bayer breakup looks possible, but it shouldn't be taken for granted even if the U.S. Supreme Court ruled in the company's favor in a case over its Roundup weedkiller, Jefferies analysts say in a research note. While many think the Supreme Court ruling could make a breakup more likely, the challenges the group's pharma business would face as a standalone company remain a potential hurdle, the analysts say. The German group's pharma business is expected to grow at a slower pace than peers over the next five years, and a couple of drugs that should help drive that growth will face risk from rival products, they add. Moreover, its drug pipeline is at an early stage, and its debt load leaves little room for acquisitions, according to Jefferies. Shares fall 0.6%.  Dow Jones NewswiresJune 26, 2026 04:20 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4007":"制药"},"translate_title":"尽管最高法院获胜，拜耳潜在分拆仍面临挑战","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"0817 GMT - A Bayer breakup looks possible, but it shouldn't be taken for granted even if the U.S. Supreme Court ruled in the company's favor in a case over its Roundup weedkiller, Jefferies analysts say in a research note. While many think the Supreme Court ruling could make a breakup more likely, the challenges the group's pharma business would face as a standalone company remain a potential hurdle, the analysts say. The German group's pharma business is expected to grow at a slower pace than peers over the next five years, and a couple of drugs that should help drive that growth will face risk from rival products, they add. Moreover, its drug pipeline is at an early stage, and its debt load leaves little room for acquisitions, according to Jefferies. Shares fall 0.6%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2026 04:20 ET (08:20 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646201337","isCrawlerRequest":true}